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Objective: To evaluate for the first time the efficacy of safe-sourced phosphatidylserine-
containing omega-3 long chain polyunsaturated fatty acid (PS-omega-3) in improving memory 
abilities.
Methods: PS-omega-3 was administered daily for 6 weeks to eight elderly volunteers with 
subjective memory complaints. The Cognitive Drug Research test battery was used to assess 
the effect on their cognitive abilities.
Results: PS-omega-3 supplementation resulted in 42% increase in the ability to recall words 
in the delayed condition.
Conclusion: PS-omega-3 may have a favorable effect on memory in subjects with subjective 
memory complaints. PS-omega-3 may serve as a safe alternative to phosphatidylserine extracted 
from bovine cortex.
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Introduction
Declines in cognitive functions, such as memory, are characteristic of normal aging.1,2 
Several age-related neurochemical changes have been associated with biochemical, struc-
tural, and functional neuronal membrane alterations, such as changes in the composition 
and/or content of lipids, leading to a loss in membrane fluidity.3 There is a growing body 
of scientific findings supporting the crucial role of phosphatidylserine (PS) in improving 
and reversing this neurochemical damage caused by age and/or disease.4
Indeed, PS has been shown to play a key role in the functioning of neuron 
membranes, such as signal transduction, secretory vesicle release, cell-to-cell 
communication, and cell growth regulation.5
Early observations associated the administration of PS extracted from bovine cortex 
(BC-PS) with positive effect on brain function. Supplementation of BC-PS (300 mg 
PS/d) to subjects with age-associated memory impairment (AAMI) resulted in improved 
performance in tests related to attention, learning, and memory tasks of daily life. 
Interestingly, some of the tested parameters improved even following short-term admin-
istration (3 weeks).6 Providing BC-PS (300 mg PS/d) to geriatric patients significantly 
enhanced behavioral and cognitive parameters.7 Importantly, BC-PS supplementation to 
patients with Alzheimer’s disease had positive effect on their cognitive performance.8,9 
The abovementioned clinical evidence is supported by numerous preclinical studies in 
which supplementation with BC-PS has been shown to attenuate neuronal effects of Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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aging and restoring normal memory on a variety of tasks. 
In these studies, BC-PS has been shown to affect multiple 
neurochemical systems, neuronal membranes,10 cell metabo-
lism,4 and neurotransmitter systems including acetylcholine,11 
norepinephrine,12 serotonin, and dopamine.13
Due to safety concerns of the risk for prion contamination 
in BC-PS, soybean-derived PS (SB-PS) was established as a 
safe alternative. SB-PS, however, differs considerably from 
BC-PS, mainly in the absence of docosahexaenoic acid (DHA), 
which is the predominant omega-3 long chain polyunsaturated 
fatty acid (LC-PUFA) in the mammalian central nervous sys-
tem. Indeed, inconclusive results have been obtained following 
interventions of SB-PS to AAMI subjects.14,15
In the present exploratory open trial, we evaluated for 
the first time the efficacy of a safe-sourced PS with omega-3 
LC-PUFA attached to its backbone (PS-omega-3), in 
treating subjective memory complaints following short-term 
administration.
Methods
subjects
A total of eight men and women volunteers aged $60 years 
with subjective memory complaints were recruited through an 
advertisement in the local newspaper in Haifa, Israel. Subjects 
were excluded from the study if used coexisting medication or 
supplement, which influences cognitive performance, had his-
tory of hypersensitivity or allergy to soy or fish, or were unable 
to perform the cognitive tests in Hebrew. Informed consent 
was obtained from all subjects. The study was approved by 
the Ethics Committee of the University of Haifa, Israel.
study design and supplement
The study was designed as a single-center, open-label study. 
Duration of treatment was 6 weeks. All participants received 
three PS-omega-3 capsules (Sharp-PS® GOLD; Enzymotec 
LTD, Migdal HaEmeq, Israel) per day. The daily dosage con-
tained 300 mg PS and 37.5 mg Eicosapentaenoic acid + DHA. 
For treatment adherence monitoring, the treatment packs 
were returned at the end of the study, and compliance was 
calculated based on number of capsules remaining.
Outcome measures
Cognitive outcome measures
Subjects were evaluated for their cognitive performance at 
baseline and at study termination (6 weeks) using the Cognitive 
Drug Research (CDR) computerized assessment battery.16 
Participants were engaged in a training session for a week 
before baseline measures and treatment initiation, in order 
to generate a common level of familiarity with the task. On 
each testing session, parallel but equivalent forms of the tests 
were presented.
The CDR battery includes nine separate tasks and 
five composite factors calculated from the results on the 
single tasks.17 “Power of attention” factor is derived by com-
bining the reaction times of the three attentional tasks (simple 
and choice reaction time and digit vigilance). “Continuity 
of attention” factor is derived by calculating the combined 
percentage accuracy across the choice reaction time and 
digit vigilance tasks. “Quality of working memory” factor 
is derived by combining the percentage accuracy scores 
from the two working memory tests (spatial and numeric 
working memory). “Quality of episodic secondary memory” 
factor is derived by combining the composite score working 
memory with the percentage accuracy scores from all second-
ary memory tests (recognition and recall tests). “Speed of 
memory” factor is derived by combining the reaction times of 
the four memory tasks (delayed picture and word recognition, 
numeric working memory, and spatial memory).
subjective mood measure
Mood was assessed by the Bond-Lader Visual Analog Scales 
of Mood and Alertness (computerized version of the test), 
consisting of 16 analog scales which are combined, as rec-
ommended by Bond and Lader18 to form three assessments: 
alertness, contentment, and calmness.
statistical methods
The Wilcoxon signed-rank test was used to test the improve-
ment from baseline to follow-up visit at 6 weeks. This nonpara-
metric test was selected due to the small numbers and the 
deviation from normality of the cognitive measures. P , 0.05 
was considered significant, without correction for multiple 
comparisons.
Analysis was done using SPSS software (version 17; 
SPSS Inc, Chicago, IL).
Results
A total of eight elderly volunteers (three men and five women) 
with subjective memory complaints were enrolled in the 
study. The mean age of subjects was 69.3 years (standard 
deviation 3.2). The treatment was well tolerated, and no 
adverse events were reported. All subjects completed the 
study and were, therefore, eligible for statistical analyses.
CDR outcome measures
Task outcomes in the order they were undertaken, and 
performance data are presented in Table 1. Following Clinical Interventions in Aging 2010:5
Table 1 effect of Ps-omega-3 on individual task outcome measures and cognitive factor scores from the CDR battery. Mean baseline 
and study termination scores are presented (with standard errors of the mean)
CDR measure Baseline Six weeks P
Individual task
Immediate word recall (% accuracy) 36.67 ± 4.36 36.67 ± 6.42 0.854
simple reaction time (ms) 338.80 ± 23.82 346.20 ± 8.16 0.889
Digit vigilance targets detected (%) 98.33 ± 0.91 97.22 ± 1.17 0.414
Digit vigilance false alarms (#) 2.00 ± 0.57 1.50 ± 0.42 0.518
Digit vigilance reaction time (ms) 467.40 ± 17.56 491.50 ± 18.65 0.036
Choice reaction time accuracy (%) 97.00 ± 1.13 96.75 ± 1.19 0.783
Choice reaction time (ms) 554.30 ± 18.68 544.60 ± 16.07 0.484
spatial working memory sensitivity index (#) 0.97 ± 0.01 0.96 ± 0.02 0.786
spatial working memory reaction time (ms) 1199.00 ± 107.00 1084.00 ± 61.08 0.161
numeric working memory sensitivity index (#) 0.96 ± 0.02 0.94 ± 0.04 0.588
numeric working memory reaction time (ms) 932.20 ± 56.28 979.20 ± 74.50 0.401
Delayed word recall (% accuracy) 20.00 ± 4.36 28.33 ± 7.43 0.041
Decay immediate to delayed word recall  
(% accuracy)
16.67 ± 3.09 8.335 ± 3.51 0.027
Word recognition sensitivity index (#) 0.66 ± 0.06 0.76 ± 0.05 0.141
Word recognition reaction time (ms) 1063.00 ± 79.51 1108.00 ± 77.45 0.484
Picture recognition sensitivity index (#) 0.76 ± 0.05 0.74 ± 0.06 0.484
Picture recognition reaction time (ms) 1203.00 ± 79.83 1254.00 ± 55.94 0.674
Cognitive factor
Power of attention 1360.5 ± 51.9 1382.3 ± 36.2 0.484
Continuity attention 90.8 ± 1.0 90.6 ± 0.8 0.916
Quality of working memory 1.93 ± 0.03 1.90 ± 0.04 0.612
Quality of episodic secondary memory 189.8 ± 13.1 205.6 ± 21.5 0.208
speed of memory 4397.3 ± 270.0 4425.1 ± 198.6 0.889
Note: The sensitivity index is calculated from formulae presented by Frey and Colliver21 and combines the accuracy scores to the original and the novel distracter 
information.
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Ps-omega-3 effect on memory abilities
treatment with PS-omega-3, the immediate word recall 
capability was generally unaffected; nonetheless, the ability 
to recall the words after a delay displayed a statistically 
significant (P = 0.041) improvement, which resulted in a 
significant decrease (P = 0.027) in the decay in memory loss 
from immediate to delayed recall.
No significant effect was obtained for the rest of CDR 
composite scores; however, a statistically significant 
(P = 0.036) decline in the speed of detections in the vigilance 
task was observed.
Mood assessment
None of the mood parameters (alertness, contentment, and 
calmness) were affected by the treatment (data not shown).
Discussion
This present pilot study tested the effect of PS-omega-3 
consumption on the memory abilities of subjects with 
subjective memory complaints. The key finding of this 
exploratory study indicates that PS-omega-3 may have a 
favorable effect on memory recall in subjects with subjective 
memory complaints, specifically on the ability to store, hold, 
and retrieve information of an episodic nature. PS-omega-3 
supplementation resulted in a significant increase of 42% in 
the ability to recall words in the delayed condition. As imme-
diate word recall for the group remained unchanged over the 
period, the increase in delayed recall would reflect a decline 
in the decay of information held in episodic memory.
The study group was well trained on the tasks prior to the 
study, and thus, we would not expect training effects to be 
responsible for any changes. Though the trial was not placebo 
controlled, data from a previously reported clinical study 
on healthy middle-aged volunteers showed a mean change 
from baseline score of 3.5 points in delayed recall following 
4 weeks treatment in the placebo group, which dropped to 
1.9 points at week 8.17 This is clearly smaller than the mean 
change of 8.3 points observed in the present study. Together, 
this may provide support for the effects being genuine; though, 
of course, placebo-controlled data are the gold standard.
It is important to note the decline in the speed of detection in 
the vigilance task; however, this increase in reaction time is hard 
to interpret, since no other attention parameters were affected.Clinical Interventions in Aging
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal
Clinical Interventions in Aging is an international, peer-reviewed journal 
focusing on evidence-based reports on the value or lack thereof of treat-
ments intended to prevent or delay the onset of maladaptive correlates 
of aging in human beings. This journal is indexed on PubMed Central, 
MedLine, the American Chemical Society’s ‘Chemical Abstracts 
Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
316
Richter et al
The observed benefit of PS-omega-3 on memory is consistent 
with previous clinical studies in which administration of PS 
resulted in significant benefits on memory skills in cognitively 
impaired population following a short supplementation period4 
and with recent studies which demonstrated the beneficial effects 
of PS with omega-3 LC-PUFA attached to its backbone.19,20
Although the results of this pilot study are encouraging, 
we acknowledge certain limitations in the study design. First, 
due to the exploratory nature of this study, we chose not to 
correct for multiple testing; therefore, the study findings 
should be tested in a confirmatory study. Second, the study 
sample was small on one hand, and lacking a control group 
on the other, an issue which again emphasizes the need for 
a following confirmatory study. Lastly, the inclusion criteria 
did not determine any prerequisite of a tested memory impair-
ment of the subject, but rather was based on participants’ 
subjective memory complaints.
To conclude, the current exploratory study shows for 
the first time that consumption of safe source PS-omega-3 
might have ameliorating effect on memory capabilities of the 
elderly population. The results of this pilot trial could assist 
in planning a future, larger scale placebo-controlled study to 
evaluate the effect of PS-omega-3 on cognitive impairment 
in elderly population.
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